We are live on ! Find out more
AAP

Aristotle Atlantic Partners Portfolio holdings

AUM $2.14B
1-Year Est. Return 37.01%
This Fund
S&P 500
This Quarter Est. Return
+10.57%
1 Year Est. Return
+37.01%
3 Year Est. Return
+123.74%
5 Year Est. Return
+154.13%
10 Year Est. Return
–
AUM
$1.52B
AUM Growth
+$149M
Cap. Flow
+$21.3M
Cap. Flow %
1.41%
Top 10 Hldgs %
42.95%
Holding
104
New
3
Increased
64
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.9M
2
SNOW icon
Snowflake
SNOW
+$10M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$5.7M
4
OGN icon
Organon & Co
OGN
+$1.9M
5
MSFT icon
Microsoft
MSFT
+$1.41M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$16.1M
2
AYX
Alteryx Inc
AYX
+$6.07M
3
QRVO icon
Qorvo
QRVO
+$3.5M
4
MRK icon
Merck
MRK
+$2.06M
5
GTLS
Chart Industries
GTLS
+$610K

Sector Composition

Rank Sector Weight
1 Technology 30.49%
2 Healthcare 20.63%
3 Consumer Discretionary 12.82%
4 Industrials 11.64%
5 Financials 9.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VZ icon
101
Verizon
VZ
$194B
$224K 0.01%
4,000
– –
MO icon
102
Altria Group
MO
$122B
– –
-4,080
Closed -$209K
AYX
103
DELISTED
Alteryx Inc
AYX
– –
-73,133
Closed -$6.07M
GWPH
104
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-1,500
Closed -$325K
1 2 3 4
5

Similar funds

SC
SouthState Corp Winter Haven, Florida $2.14B AUM 18.39% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
NAAA
New Age Alpha Advisors Rye, New York $2.15B AUM 27.2% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
GHA
GW Henssler & Associates Kennesaw, Georgia $2.12B AUM 20.77% 1-Year Est. Return
BCM
Basswood Capital Management New York $2.12B AUM 19.53% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.15B AUM 20.86% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

Aristotle Atlantic Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Aristotle Atlantic Partners held 104 positions worth $1.52B, up 11% from $1.37B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Aristotle Atlantic Partners's Q2 2021 filing shows 3 new, 64 increased, 4 reduced and 3 closed positions. Its largest new stake was Vertex Pharmaceuticals: 61,548 shares worth $12.4M. The largest sale was Cigna, an estimated $16.1M.

By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 29% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Aristotle Atlantic Partners's largest Q2 2021 buy was Vertex Pharmaceuticals: 61,548 shares worth $12.4M.
  • Aristotle Atlantic Partners added most to Adaptive Biotechnologies in Q2 2021, an estimated $5.7M increase.
  • Aristotle Atlantic Partners's biggest Q2 2021 reduction was Cigna, cutting an estimated $16.1M.
  • Aristotle Atlantic Partners fully exited Alteryx Inc in Q2 2021, selling an estimated $6.07M.
  • Aristotle Atlantic Partners's ten largest holdings make up 43% of its $1.52B portfolio in Q2 2021.
  • Aristotle Atlantic Partners opened 3 new positions and closed 3 in Q2 2021.
  • Aristotle Atlantic Partners's portfolio value rose 11% quarter-over-quarter to $1.52B.

Based on Aristotle Atlantic Partners's 13F filing for Q2 2021, filed 16 Aug 2021.